09/21/15 - 12:50 PM EDT
The major biotech stock indices fell Monday minutes after Democratic presidential candidate Hillary Clinton tweeted that she'll release a plan to tackle escalating drug prices on Tuesday.
09/18/15 - 06:11 AM EDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
09/16/15 - 02:24 PM EDT
Slightly more than 300 out of a required 348 brain tumor patients are currently enrolled in Northwest Bio's DCVax-L phase III study.
09/16/15 - 11:10 AM EDT
Schizophrenia patients treated with an experimental drug from Intra-Cellular Therapies reported fewer antipsychotic symptoms compared to a placebo in a large, phase III study, the company said Wednesday.
09/16/15 - 09:47 AM EDT
Amgen is acquiring a privately held company developing a cholesterol-lowering pill just weeks after receiving approval for its own cholesterol-lowering injection.
09/15/15 - 09:59 AM EDT
An experimental pill from Xenoport reduced psoriasis skin symptoms significantly more than a placebo in a mid-stage study, but a high rate of diarrhea raises questions about the drug's future.
09/14/15 - 06:27 AM EDT
A Tetraphase insider executed a well-timed insider stock sale right before the company's share price fell on negative clinical trial results.
09/10/15 - 11:39 AM EDT
FDA missed a deadline earlier this week to finalize the Biomarin/Sarepta advisory panels on Nov. 23-24, if (and only if) Nov. 23-24 were the chosen dates.
09/10/15 - 11:00 AM EDT
Spark Therapeutics provided details Thursday about changes made to a clinical trial involving the company's gene therapy, trying to calm jittery biotech investors before study results next month.
09/09/15 - 09:24 AM EDT
Biogen stepped into the oral S1P modulator race Wednesday with the acquisition of a license to develop a mid-stage compound from Japan's Mitsubishi Tanabe Pharma.